Evidence map›Paper›PMID 33111205›Full record

ArticleInternational journal of clinical oncology2021

Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma.

Kenichi Miyamoto, Takashi Watanabe, Masashi Wakabayashi, Kenichi Nakamura, Yuko Watanabe, Dai Maruyama, Kensei Tobinai, Kunihiro Tsukasaki, Haruhiko Fukuda

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Clinical effect of hepatic artery interventional embolization and chemotherapy and its influence on P16 protein expression in patients with liver cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Kenichi MiyamotoJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, 5-1-1, Tsukiji, Chu-o-ku, Tokyo, 104-0045, Japan. sp9y5nm9@gmail.com.ORCID http://orcid.org/0000-0002-1848-2760
Takashi WatanabeDepartment of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Mie, Japan.
Masashi WakabayashiJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, 5-1-1, Tsukiji, Chu-o-ku, Tokyo, 104-0045, Japan.
Kenichi NakamuraJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, 5-1-1, Tsukiji, Chu-o-ku, Tokyo, 104-0045, Japan.
Yuko WatanabeJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, 5-1-1, Tsukiji, Chu-o-ku, Tokyo, 104-0045, Japan.
Dai MaruyamaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Kensei TobinaiDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Kunihiro TsukasakiDepartment of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan.
Haruhiko FukudaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, 5-1-1, Tsukiji, Chu-o-ku, Tokyo, 104-0045, Japan.
Japan Clinical Cancer Research Organization · JPTokyo National Hospital · JPMie University · JPSaitama Medical University · JP

Funding

the National Cancer Center Research and Development Fund 26-A-4the National Cancer Center Research and Development Fund 29-A-3
6 · The paper itself

Abstract

background[

methodsTo evaluate the degree of agreement between them, the Kappa coefficient (KC) was calculated. Excluding patients without target lesions for the RECIST following central pathological review, 269 patients were evaluable. We determined which criterion was more predictive for progression-free survival. The criterion showing the lower point estimate of the hazard ratio (HR) of a complete response (CR) vs. a non-CR was defined as more useful.

resultsThe KC between them was 0.34 (95% confidence interval [CI] 0.26-0.42); namely, indicating poor agreement. The HR of the IWC (0.47: 95% CI 0.33-0.68, log-rank test p < 0.001) was lower than that of the RECIST (0.64: 95% CI 0.45-0.89, p = 0.0075).

conclusionWe conclude that unidimensional measurements cannot be substituted for the bidimensional ones for indolent lymphoma.

Indexed as

Lymphoma, B-CellHumansPositron-Emission TomographyResponse Evaluation Criteria in Solid TumorsTreatment OutcomeFollicular lymphomaIndolent B-cell lymphomaInternational Workshop CriteriaJCOGRECIST

Identifiers

PMID33111205
OpenAlexW3095997785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.